Wyeth Sues Watson Over Birth Control Patent

Law360, New York (March 14, 2008, 12:00 AM EDT) -- Wyeth has filed suit against Watson Pharmaceuticals Inc., claiming the generic-drug maker infringed a patent for its birth control drug Lybrel by submitting an abbreviated new drug application to the U.S. Food and Drug Administration.

In a complaint filed Tuesday in the U.S. District Court for the District of Delaware, Wyeth alleges the product proposed by Watson, which claims to be the first company to file an ANDA for generic Lybrel, will infringe its patent covering the method of producing a contraceptive product using two hormone...
To view the full article, register now.